January 23-25, 2018

San Francisco, CA

REGISTER TO ATTEND NOW – SAVE $300

Day One
Wednesday January 24th, 2017

Day Two
Thursday, January 25th 2018

08.30
Registration

09.00
Chairperson’s Opening Remarks

09.40
Characterization of ADME Properties of Novel Protein Therapeutics

Synopsis

  • Next generation protein therapeutics are engineered in an attempt to improve the efficacy of monoclonal antibody therapeutics in the oncology setting.
  • Designing multifunctional therapeutics for enhanced pharmacologic activity or improved target selectivity.
  • Altering the targeting and/or activity of a molecule can concomitantly lead to novel and unanticipated ADME properties and pharmacokinetics for the therapeutic.
  • Characterization of the stability and overall disposition of bispecific antibodies and antibody-cytokine fusion proteins to help guide engineering and selection of lead candidates.

10.10
Understand Preclinical Pharmacokinetics and ADME of Bispecific T-cell Engagers

Synopsis

  • Bispecific T-cell engagers represent novel class of protein molecules wherein engineering efforts can impact pharmacokinetics and pharmacologic activity.
  • Understand the importance of preclinical experimental design criteria for translation to the clinic.

10.40
Novel Bone Metastasis Models in Syngeneic and Humanized Mice

Synopsis

  • Importance of tumor microenvironment
  • Testing antitumor efficacy in bone metastasis models
  • Immunotherapy and bone

10.40
Morning Refreshments

11.50
Strategies for Using Models In CAR T Cell Research and Development

  • Rafael Ponce Sr. Director, Preclinical Sciences, Juno Therapeutics

Synopsis

  • Optimizing your preclinical models for CAR T cell research and development
  • Challenges involved when characterizing your preclinical models for Car T cell research

12.20
Utilization of Murine Breast Cancer Models in Preclinical Immuno-Oncology Pharmacology

  • Dylan Daniel Director - Scientific Development, MI Bioresearch

Synopsis

  • Pros and Cons of the 4T1 Mammary Cancer Model
  • Characteristics of Alternative Syngeneic Breast Models
  • Responses of a New Model to Checkpoint Inhibition and T Cell Costimulation

12.40
Optimizing Preclinical Models for The Development of T Cell Dependent Bispecific (TDBs) Antibody Therapies Targeting Solid Tumors

Synopsis

  • Overview of TDB antibodies
  • Limitations of using syngeneic and GEMM in vivo models to demonstrate antitumor
    efficacy of TDBs in solid tumors
  • Utilizing the huPBMC transfer model in NSG mice to demonstrate efficacy and
    establish preclinical therapeutic index of TDB antibodies

13.10
Lunch and Networking

14.10
Multiplexing CAR T Cell Therapy

Synopsis

  • Bispecific CARs targeting 2 antigens in ALL
  • Multiplexing CAR with regulatory CARs
  • How to track multiple CARs In Vitro and In Vivo

14.40
Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies & Immunotherapies

  • Andrew Rhim CPRIT Scholar in Cancer Research, Associate Director for Translational Research , in Pancreatic Cancer Research, MD Anderson Cancer Center

Synopsis

  • Describing models used and key considerations for experimental design
  • Model responses and predictability of combination efficacy

15.10
Chairperson’s Closing Remarks

15.15

Close of the Annual Tumor Models San Francisco Summit


9.10
Transforming Translational Research: CANscript™ – A Better Predictive Model For Oncology

  • Mark Paris Associate Director, Translational Applications Biopharma Business Development, Mitra Biotech Inc.

Synopsis

  • Mitra Biotech has developed and clinically validated fully human ex-vivo platform technology (CANscript™)
  •  CANscript ™ uses patient material (tumor, autologous ligands and immune cells) to explore the mechanism of and predict efficacy for clinically-directed compounds across several drug classes
  •  This talk will explore how CANscript can better enable your translational efforts and aid in advancing your highest potential candidate into successful clinical trials